ciprofloxacin has been researched along with etoposide in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.22) | 18.7374 |
| 1990's | 7 (15.56) | 18.2507 |
| 2000's | 12 (26.67) | 29.6817 |
| 2010's | 25 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Avdeef, A; Tam, KY | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bao, L; Cai, L; Chen, JL; Huang, P; Liu, HW; Liu, MM; Qi, QY; Wang, QX; Yang, JL; Yang, XL; Zhang, LX | 1 |
| Jardosh, HH; Patel, MP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Abdel-Aziz, M; Abuo-Rahma, Gel-D; Kwon, Y; Park, SE; Sayed, MA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Crespín, GD; Daranas, AH; Febles, M; Fernández, JJ; Montalvão, S; Norte, M; Padrón, JM; Tammela, P | 1 |
| Amesty, Á; Anaissi-Afonso, L; Estévez-Braun, A; Hueso-Falcón, I; Lorenzo-Castrillejo, I; Machín, F | 1 |
| Gedawy, EM; Kassab, AE | 1 |
| Benedetto Tiz, D; Draskovits, G; Durante Cruz, C; Durcik, M; Ilaš, J; Kikelj, D; Lovison, D; Nyerges, Á; Pál, C; Peterlin Mašič, L; Skok, Ž; Tammela, P; Tomašič, T; Zidar, N | 1 |
| Dellos-Nolan, S; English, A; Karmahapatra, S; Li, L; Li, Z; Mitton-Fry, MJ; Okumu, A; Wozniak, DJ; Yalowich, JC | 1 |
| Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
| Cruz, CD; Draskovits, G; Durcik, M; Ilaš, J; Kikelj, D; Mašič, LP; Nyerges, Á; Pál, C; Révész, T; Skok, Ž; Tammela, P; Tiz, DB; Tomašič, T; Zega, A; Zidar, N; Žigon, D | 1 |
| Brant, M; Bredberg, A; Jaszyk, M | 1 |
| Forterre, P; Sioud, M | 1 |
| Kato, M; Takada, S; Takayama, S | 1 |
| Agarwal, K; Mukherjee, A; Sen, S | 1 |
| Burgess, R; Dawson, D; Haller, J | 1 |
| Burden, DA; Elsea, SH; Lomenick, JP; Osheroff, N; Westergaard, M | 1 |
| Rowe, TC; Vetro-Widenhouse, TS; Weissig, V | 1 |
| Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP | 1 |
| Chatterji, M; Mahadevan, S; Nagaraja, V; Unniraman, S | 1 |
| Bunn, PA | 1 |
| Ardizzoni, A; Postmus, PE; Tjan-Heijnen, VC | 1 |
| Aranha, O; Aslam, N; El-Rayes, BF; Grignon, R; Sarkar, FH | 1 |
| Andresen, SW; Avery, RK; Bernhard, L; Bolwell, BJ; Goormastic, M; Kalaycio, ME; Kuczkowski, E; Longworth, DL; Mossad, SB; Ostendorf, H; Pohlman, BL; Sobecks, RM; Wise, K | 1 |
| Aylott, M; Burman, M; Harvey, J; Lynch, A; Nicholas, E; Rees, R; Siddiqui, A; Walker, S | 1 |
| Adang, EM; Akkermans, J; Biesma, B; Bootsma, GP; Cheragwandi, SA; de Boo, TM; Hensing, CA; Smit, HJ; Termeer, A; Timmer-Bonte, JN; Tjan-Heijnen, VC; Wilschut, FA | 1 |
| Boudabous, A; Cekaite, L; Sioud, M | 1 |
| Ângelo, S; Moreira, JN; Pinto, AC; Simões, S | 1 |
| Egbert, SF; Hartemink, KJ; Koen, HJ; Marinus, PA; Paul, MA; Pieter, PE; Postmus, PE; Romane, SM; Schook, RM; Smit, EF | 1 |
| Herbrecht, R; Jarfaut, A; Levêque, D; Santucci, R | 1 |
| Nenortas, E; Shapiro, TA; Tang Girdwood, SC | 1 |
3 review(s) available for ciprofloxacin and etoposide
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
1 trial(s) available for ciprofloxacin and etoposide
| Article | Year |
|---|---|
Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Ciprofloxacin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Risk Factors; Roxithromycin; Treatment Outcome | 2005 |
41 other study(ies) available for ciprofloxacin and etoposide
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
3-Anhydro-6-hydroxy-ophiobolin A, a new sesterterpene inhibiting the growth of methicillin-resistant Staphylococcus aureus and inducing the cell death by apoptosis on K562, from the phytopathogenic fungus Bipolaris oryzae.
Topics: Apoptosis; Cell Death; Drug Screening Assays, Antitumor; Flow Cytometry; Hep G2 Cells; Humans; K562 Cells; Methicillin-Resistant Staphylococcus aureus; Oryza; Sesterterpenes; Structure-Activity Relationship | 2013 |
Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antitubercular Agents; Artemia; Bacteria; Dose-Response Relationship, Drug; Drug Design; Fungi; Isoniazid; Microbial Sensitivity Tests; Molecular Structure; Motor Activity; Quinolones; Structure-Activity Relationship; Tuberculosis | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chalcone; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Piperazines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2013 |
Synthesis and biological evaluation of crown ether acyl derivatives.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Candida albicans; Candidiasis; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Screening Assays, Antitumor; Humans; Neoplasms; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Synthesis and biological evaluation of naphthoquinone-coumarin conjugates as topoisomerase II inhibitors.
Topics: Coumarins; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Molecular Structure; Naphthoquinones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Bacillus subtilis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Escherichia coli; Humans; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa; Staphylococcus aureus; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
Topics: Amides; Anti-Bacterial Agents; DNA Gyrase; Dose-Response Relationship, Drug; Enterococcus faecalis; Escherichia coli; Microbial Sensitivity Tests; Molecular Structure; Pyrroles; Staphylococcus aureus; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety.
Topics: Anti-Bacterial Agents; Crystallography, X-Ray; Dioxanes; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Potassium Channel Blockers; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
Topics: Amides; Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Topoisomerase II Inhibitors | 2019 |
Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells.
Topics: Cell Line; Ciprofloxacin; DNA; DNA Topoisomerases, Type II; Etoposide; Humans; Topoisomerase II Inhibitors | 1991 |
Ciprofloxacin and etoposide (VP16) produce a similar pattern of DNA cleavage in a plasmid of an archaebacterium.
Topics: Ciprofloxacin; DNA Damage; Etoposide; Halobacterium; Novobiocin; Plasmids | 1989 |
Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles.
Topics: Administration, Oral; Animals; Bleomycin; Camptothecin; Cartilage, Articular; Chondroitin Lyases; Ciprofloxacin; Collagenases; Cycloheximide; Ethylmaleimide; Etoposide; Fluorescent Dyes; Hydroxyurea; Injections, Intra-Articular; Iodoacetates; Iodoacetic Acid; Irinotecan; Levofloxacin; Male; Ofloxacin; Papain; Rats; Rats, Sprague-Dawley; Rhodamines; Topoisomerase I Inhibitors | 1994 |
Ciprofloxacin: mammalian DNA topoisomerase type II poison in vivo.
Topics: Analysis of Variance; Animals; Bone Marrow Cells; Chromosome Aberrations; Ciprofloxacin; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Male; Mice; Mutagenicity Tests; Mutagens; Sister Chromatid Exchange | 1993 |
Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin with VP-16 and ciprofloxacin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Ciprofloxacin; Cisplatin; Drug Screening Assays, Antitumor; Etoposide; Head and Neck Neoplasms; Humans; Tumor Cells, Cultured | 1993 |
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; CHO Cells; Ciprofloxacin; Cricetinae; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Electrophoresis, Agar Gel; Enzyme Activation; Etoposide; Fluoroquinolones; Genistein; Isoflavones; Kinetics; Molecular Structure; Quinolones | 1997 |
Topoisomerase II inhibitors induce cleavage of nuclear and 35-kb plastid DNAs in the malarial parasite Plasmodium falciparum.
Topics: Animals; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Circular; DNA, Protozoan; Enzyme Inhibitors; Etoposide; Exonucleases; Hot Temperature; Plasmodium falciparum; Topoisomerase II Inhibitors | 1997 |
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Topics: Anti-Infective Agents; Biological Evolution; Ciprofloxacin; DNA Damage; DNA Repair; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Escherichia coli; Etoposide; Fluoroquinolones; Gram-Positive Bacteria; Kinetics; Quinolones; Staphylococcus aureus | 1999 |
Effect of different classes of inhibitors on DNA gyrase from Mycobacterium smegmatis.
Topics: Adenosine Triphosphatases; Anti-Infective Agents; Bacterial Proteins; Bacterial Toxins; Bacteriocins; Ciprofloxacin; DNA Gyrase; Enzyme Inhibitors; Escherichia coli; Etoposide; Mycobacterium smegmatis; Nucleic Acid Synthesis Inhibitors; Plasmids; Topoisomerase II Inhibitors | 2001 |
Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Ciprofloxacin; Cyclophosphamide; Doxorubicin; Endpoint Determination; Etoposide; Fever; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Research Design; Roxithromycin | 2001 |
Reply to the article "Editorial comments on 'reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'", by P.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Ciprofloxacin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Etoposide; Fever; Humans; Lung Neoplasms; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Roxithromycin | 2002 |
Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Division; Ciprofloxacin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Down-Regulation; Drug Synergism; Electrophoretic Mobility Shift Assay; Etoposide; Gene Expression Regulation; Humans; Male; Middle Aged; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Tumor Cells, Cultured | 2002 |
The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization.
Topics: Ambulatory Care; Antibiotic Prophylaxis; Cefepime; Cephalosporins; Ciprofloxacin; Clarithromycin; Data Collection; Drug Therapy, Combination; Etoposide; Female; Fever; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Neutropenia; Opportunistic Infections; Vancomycin | 2002 |
Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity.
Topics: Animals; Anti-Infective Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Genistein; Lymphoma; Mice; Mutagens; Topoisomerase I Inhibitors | 2003 |
Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Bacillus subtilis; Bacillus thuringiensis; Ciprofloxacin; DNA; DNA Gyrase; Etoposide; Gene Expression Regulation; Novobiocin; Plasmids; SOS Response, Genetics; Transcription, Genetic | 2009 |
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Etoposide; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Mitoxantrone; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms; Pyrimidines; Vinblastine | 2011 |
Benefit of a second opinion for lung cancer: no recurrent disease, but infection.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Ciprofloxacin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Postoperative Care; Prognosis; Referral and Consultation | 2012 |
Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bicarbonates; Bleomycin; Ciprofloxacin; Crystallization; Cyclophosphamide; Cytarabine; Diarrhea; Doxorubicin; Drug Eruptions; Drug Interactions; Etoposide; Female; Fluid Therapy; Fungemia; Humans; Hydrogen-Ion Concentration; Ifosfamide; Lymphoma, B-Cell; Mediastinal Neoplasms; Metabolic Clearance Rate; Methotrexate; Mucositis; Pancytopenia; Prednisone; Solubility; Urine; Vindesine | 2013 |
Targeting the gyrase of Plasmodium falciparum with topoisomerase poisons.
Topics: Antimalarials; Apicoplasts; Ciprofloxacin; DNA Gyrase; Etoposide; Fluoroquinolones; Genome, Protozoan; Plasmodium falciparum; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2015 |